Deliver Your News to the World

CytoGenix to Present at the European BioPharm Scale-Up Congress 2007 in Switzerland


Houston, TX - CytoGenix, Inc. (CYGX.OB) announced today that Dr. Yin Chen, Chief Scientific Officer was invited to present an overview of the Company’s proprietary synDNA™ technology at the European BioPharm Scale-Up Congress 2007 held in Geneva, Switzerland from September 11 to September 13th.

Dr Chen’s presentation featured in the “Addressing a Pandemic Through Rapid Scaled-Up” session focuses on technology developed by the Company’s scientists for producing DNA vaccines using a novel non-fermentation process with emphasis on current application successes and its use in rapid response against biological threats.

Dr. Chen comments, “This Congress was especially organized to have pharmaceutical and biotech industry leaders meet and share information and results regarding the development of new ways to produce biopharmaceuticals to counter current and future bio-threats. This is an important opportunity for CytoGenix to showcase its synDNA™ technology platform not only as a potent vaccine production method but also as a scalable rapid response process against pandemic flu or other bio-terror agents.”

CytoGenix, Inc. is a Houston-based biopharmaceutical company that develops and markets innovative products and services based on its proprietary synDNA™ production and ssDNA expression technology. The company has developed a breakthrough synthetic process for large-scale production of biologically active DNA that can be made faster and cleaner than production using traditional fermentation methods and has developed a novel expression vector that enables production of therapeutic DNA inside the cell. CytoGenix currently holds 13 granted patents and about 57 international or US pending patent applications claiming methods and materials in connection with these platform technologies.

SAFE HARBOR: Except for statements of historical fact, the statements in this press release are forward-looking. Such statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include, but are not limited to, general economic conditions, risks associated with the acceptance of new products, competition, and other factors more fully detailed in the company’s filings with the Securities and Exchange Commission. Additional information about CytoGenix and its technology can be found on the website at


This news content was configured by WebWire editorial staff. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.